TRENDS

• Surprise Rule Change Pops Up Yet Again, This Time with Taltz
  September 5, 2016

• Top Global Pharmas Lackluster in Japan while Hep C Drug Makers Flourish
  June 21, 2016

• Success of Daiichi Sankyo’s New Midterm Plan to Hinge on Edoxaban; 120 Billion Yen Sales Target Set for FY2020
  April 13, 2016

• Multiple Authorized Generics Get Approval towards June Listing as Pharmas See Opportunities
  February 17, 2016

• Japan Drug Makers Foresee 6% Sales Growth in FY2015: Jiho Tally
  February 15, 2016

• 17,800 Hep C Patients Prescribed Sovaldi in 6 Months; Clinical Benefits Out of Consideration in New Re-Pricing Rule
  January 27, 2016

• Global Pharmas Mull Excluding Japan from In-Licensing Deals on Annual Revision Fears, Softer Yen
  January 26, 2016

• Takeda’s Exit from Diabetes Research a Symbolic Move under Weber Leadership
  January 20, 2016

• Teva JV Deal Marks Turning Point in Takeda’s Japanese Business
  January 6, 2016

• “Huge Seller” Re-Pricing Targeting Hep C Drugs Will Dampen Innovative Market
  December 9, 2015

• Peak Sales Forecast for New Drugs Listed in 2015 Exceeded 840 Billion Yen with Big Contribution from Hep C Treatments
  December 7, 2015

• AG Shares Reach 50-60% in 1 Year; Confidence in Quality Encourages Dominance Even without Market Lead
  November 30, 2015

• Full-Year Forecasts for Domestic Market Down vs Previous Year; Major Makers Struggling Even in Year without NHI Price Revision
  November 11, 2015

• Shift to Specialty - 5: Eisai, Ajinomoto Jump on Specialty Bandwagon to Seek Efficiency in GI Biz
  October 30, 2015

• Drug Makers’ Payments to Medical Institutions Dip for Second Year: Jiho Tally
  September 15, 2015

• Transformation of ARB Market Spurred by AGs, Power Map Changing Fast as Brand-Name Drugs Falter
  September 4, 2015

• Japan Drug Makers See Rising Overseas Sales Ratios in April-June
  August 11, 2015

• IFN-Free Drugs Upending Hepatitis C Market Landscape
  July 17, 2015

• 3 Major Japan Makers Shed 1,300 Jobs amid Redundancy Programs
  June 30, 2015

• “80% Generic” Era Would Further Accelerate Contraction of Market for Long-Listed Drugs
  June 29, 2015

ページ